Access the medicines your patients need — before they are approved in India.
Submit a Named Patient or Early Access Program request. Sowaka manages all regulatory paperwork, import logistics, and documentation from that point forward.
Get in touch
This page is for oncologists and rare disease specialists seeking access to medicines not yet approved in India; hospital pharmacy and procurement teams evaluating unlicensed treatment options; and institutional MDT committees managing compassionate use or early access requests. If you are a patient or family member, see our patient page. If you represent a pharmaceutical company, see our pharma page.
How Sowaka works
- 1Physician or institution identifies a patient need and contacts Sowaka.
- 2Sowaka conducts a regulatory review within 72 hours and confirms eligibility.
- 3Supply chain is initiated — sourcing from US and EU licensed wholesaler network.
- 4Import documentation, customs clearance, and cold-chain logistics managed end-to-end.
- 5Medicine delivered to the treating physician or hospital pharmacy with full chain-of-custody documentation.
What programs are available
Named Patient Programs (Sowaka Cares)
For individual patients who need a specific unlicensed medicine. Each request is managed on a per-patient basis with full regulatory and logistical support.
Learn more →Early Access Programs (Sowaka Express)
For pharma-sponsored programs enabling broader pre-approval access to investigational medicines in India.
Learn more →All Named Patient Program imports are processed under Schedule H1 and Rule 32 of the Drugs and Cosmetics Rules, 1945. Sowaka Health holds a US Wholesale Drug License and operates a CDSCO-compliant import model. Full chain-of-custody documentation is provided on every order.
Online request submission is coming shortly. In the meantime, reach us directly: